Dual targeting of DR5 and VEGFR2 molecular pathways by multivalent fusion protein significantly suppresses tumor growth and angiogenesis

Isakova, A.A.; Artykov, A.A.; Plotnikova, E.A.; Trunova, G.V.; Khokhlova, V.А.; Pankratov, A.A.; Shuvalova, M.L.; Mazur, D.V.; Antipova, N.V.; Shakhparonov, M.I.; Dolgikh, D.A.; Kirpichnikov, M.P.; Gasparian, M.E.; Yagolovich, A.V.

Авторы: Isakova Alina A., Artykov Artem A., Plotnikova Ekaterina A., Trunova Galina V., Khokhlova Varvara А., Pankratov Andrey A., Shuvalova Margarita L., Mazur Diana V., Antipova Nadezhda V., Shakhparonov Mikhail I., Dolgikh Dmitry A., Kirpichnikov Mikhail P., Gasparian Marine E., Yagolovich Anne V.
Журнал: International Journal of Biological Macromolecules
Год издания: 2023
Издательство: Elsevier BV
Местоположение издательства: Netherlands
Номер статьи: 128096
DOI: 10.1016/j.ijbiomac.2023.128096
Аннотация: Destroying tumor vasculature is a relevant therapeutic strategy due to its involvement in tumor progression. However, adaptive resistance to approved antiangiogenic drugs targeting VEGF/VEGFR pathway requires the recruitment of additional targets. In this aspect, targeting TRAIL pathway is promising as it is an important component of the immune system involved in tumor immunosurveillance. For dual targeting of malignant cells and tumor vascular microenvironment, we designed a multivalent fusion protein SRH-DR5-B-iRGD with antiangiogenic VEGFR2-specific peptide SRH at the N-terminus and a tumor-targeting and -penetrating peptide iRGD at the C-terminus of receptor-selective TRAIL variant DR5-B. SRH-DR5-B-iRGD obtained high affinity for DR5, VEGFR2 and αvβ3 integrin in nanomolar range. Fusion of DR5-B with effector peptides accelerated DR5 receptor internalization rate upon ligand binding. Antitumor efficacy was evaluated in vitro in human tumor cell lines and primary patient-derived glioblastoma neurospheres, and in vivo in xenograft mouse model of human glioblastoma. Multivalent binding of SRH-DR5-B-iRGD fusion efficiently stimulated DR5-mediated tumor cell death via caspase-dependent mechanism, suppressed xenograft tumor growth by >80 %, doubled the lifespan of xenograft animals, and inhibited tumor vascularization. Therefore, targeting DR5 and VEGFR2 molecular pathways with SRH-DR5-B-iRGD protein may provide a novel therapeutic approach for treatment of solid tumors.
Добавил в систему: Яголович Анна Валерьевна

	ИСТИНА	Войти в систему Регистрация
	ИПМех РАН
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

ИПМех РАН

Dual targeting of DR5 and VEGFR2 molecular pathways by multivalent fusion protein significantly suppresses tumor growth and angiogenesisстатья Исследовательская статья